Results 31 to 40 of about 1,420 (176)
Ampreloxetine Versus Droxidopa in Neurogenic Orthostatic Hypotension: A Comparative Review. [PDF]
Cureus, 2023 Neurogenic orthostatic hypotension (nOH) is a disabling problem of autonomic dysfunction in patients with Parkinson's disease, which is associated with poor quality of life and higher mortality rates. The purpose of this literature review was to explore and compare the efficacy and safety of droxidopa (an existing treatment) and ampreloxetine (a newer ...
Hoxhaj P +12 more
europepmc +3 more sources
Prescription rate of medications potentially contributing to lower urinary tract symptoms and detection of adverse reactions by prescription sequence symmetry analysis [PDF]
, 2015 BACKGROUND: The lower urinary tract symptoms (LUTS) increases with age and can have a significant effect on the quality of life of the patients. Elderly patients, who are often characterized by a decline in physiological functional and polypharmacy, are ...
Fumihiko Ando +5 more
core +2 more sources
BMC Cardiovascular Disorders, 2020 Background Neurogenic orthostatic hypotension, a sustained decrease in blood pressure upon standing, is caused by autonomic nervous system failure and characterized by an insufficient increase in heart rate needed to maintain blood pressure upon standing.
Sameh K. Mobarek
doaj +1 more source
Prospects for Droxidopa in Neurogenic Orthostatic Hypotension [PDF]
Hypertension, 2015 See related article, pp 101–107 Neurogenic orthostatic hypotension (nOH) is a debilitating disorder defined by a sustained decrease in systolic blood pressure of 20 mm Hg or in diastolic blood pressure of 10 mm Hg within 3 minutes of head-up tilt or standing.1 The disorder is associated with attenuated increases in plasma norepinephrine and peripheral
Amanda J, Ross, Julian M, Stewart
openaire +2 more sources
Journal of Parkinson’s Disease, 2016 Background: Neurogenic orthostatic hypotension (nOH) is associated with insufficient norepinephrine release in response to postural change. Objective: The objective of this study was to evaluate the long-term safety and durability of efficacy of the ...
Stuart Isaacson +4 more
doaj +1 more source
Efficacy of Pharmacologic Treatment for Orthostatic Hypotension in the Elderly Population [PDF]
, 2021 The purpose of this literature review is to determine the efficacy and safety of pharmacologic treatments for orthostatic hypotension (OH), with an emphasis on researching the elderly population.
Moeller, Abigail
core +2 more sources
Journal of Market Access & Health Policy, 2022 Background Symptoms of neurogenic orthostatic hypotension (nOH), including lightheadedness/dizziness, presyncope, syncope, and falls, can lead to impaired functional ability and reduced quality of life.
Clément François +5 more
doaj +1 more source
Six‐Month Use of Droxidopa for Neurogenic Orthostatic Hypotension [PDF]
Movement Disorders Clinical Practice, 2019 ABSTRACTBackgroundDroxidopa is approved for adult patients with symptomatic neurogenic orthostatic hypotension (nOH); there is limited information regarding effects on symptoms, outcomes, and quality of life (QOL) beyond two weeks of treatment.ObjectiveExamine the real‐world experience of patients taking droxidopa after six months of treatment ...
François, Clément +11 more
openaire +2 more sources
Droxidopa Persistence in Neurogenic Orthostatic Hypotension May Be Affected by Titration Approach
International Journal of General Medicine, 2021 Fahd Amjad,1 Brett Polenchar,2 Antonella Favit3 1Department of Neurology, Georgetown University Hospital Pasquerilla Healthcare Center, Washington, DC, USA; 2Business Insights, Lundbeck, Deerfield, IL, USA; 3Medical Affairs, Lundbeck, Deerfield, IL ...
Amjad F, Polenchar B, Favit A
doaj
Cardiology and Therapy, 2019 Introduction The prevalence of neurogenic orthostatic hypotension (nOH) increases with age and is associated with autonomic failure in neurodegenerative diseases (e.g., Parkinson's disease).
Peter A. McCullough
doaj +1 more source